hVIVO gets HSE clearance, launches new lab services
30th Sep 2024 10:19
(Sharecast News) - Specialist contract research organisation hVIVO launched the full suite of services provided by its hLAB division - a highly specialised virology and immunology laboratory supporting preclinical and clinical drug development - on Monday.
Read moreHvivo delivers record revenues in H1, reiterates FY guidance
17th Jul 2024 08:46
(Sharecast News) - Contract research organisation Hvivo restated full-year guidance on Wednesday as the group revealed it had delivered record revenues in H1.
Read morehVIVO secures biggest field study contract to date
2nd Jul 2024 12:46
(Sharecast News) - Specialist contract research organisation hVIVO announced its engagement in a phase 2b field study for an influenza drug candidate on Tuesday.
Read moreHvivo scores £2.5m contract for Omicron characterisation study
3rd Jun 2024 10:35
(Sharecast News) - Contract research organisation Hvivo has secured a £2.5m contract with a mid-sized pharmaceutical company to initiate an Omicron characterisation study after the manufacture of its Omicron BA.5 challenge agent was successfully completed in 2023.
Read moreHvivo unveils record results and bullish growth targets
9th Apr 2024 08:58
(Sharecast News) - Shares in AIM-listed Hvivo dipped on Tuesday despite the infectious and respiratory disease treatment firm reporting a record year across all financial and operational metrics, as well as ambitious revenue targets for the coming years.
Read morehVIVO secures £6.3m contract with biotech client
2nd Jan 2024 08:56
(Sharecast News) - Infectious and respiratory disease study group hVIVO has inked a £6.3m contract with an unnamed biotechnology client to test an antiviral candidate using its common cold virus human challenge study model.
Read moreSunday share tips: hVivo and On the Beach
24th Dec 2023 11:06
(Sharecast News) - Drug-testing specialist hVivo was one of the top tips for 2023 from The Daily Mail's Midas column, but the paper still reckons there's further to go despite the stock doubling in price over the year.
Read moreHVivo jumps on contract win, guidance upgrade
13th Dec 2023 08:20
(Sharecast News) - Shares in AIM-listed HVivo jumped on Wednesday morning after the clinical trials and laboratory services group won a new £17m contract and announced it was trading ahead of guidance.
Read morehVIVO upbeat on positive results from recent FluCamp study
5th Oct 2023 15:15
(Sharecast News) - Contract research organisation hVIVO announced on Thursday that in a recent phase 2a influenza human challenge study it conducted, Pneumagen's antiviral candidate Neumifil demonstrated successful clinical proof of concept.
Read morehVIVO announces new Canary Wharf trial facility
29th Aug 2023 14:17
(Sharecast News) - Human challenge trial specialist hVIVO announced plans to open a new state-of-the-art facility at the rapidly-expanding life sciences hub in Canary Wharf, London on Tuesday.
Read morehVIVO manufactures human challenge agent for Omicron
16th Mar 2023 15:48
(Sharecast News) - Specialist contract research organisation hVIVO has successfully manufactured its Omicron human challenge agent, it announced on Thursday.
Read morehVIVO inks £5.2m contract with biotechnology group
4th Jan 2023 07:50
(Sharecast News) - Contract research organisation hVIVO has signed a £5.2m contract with a global biotechnology company to test its respiratory syncytial virus vaccine candidate.
Read moreDirector dealings: Hvivo director ups stake
8th Jan 2020 16:16
(Sharecast News) - Hvivo revealed on Wednesday that non-executive director James Winschel had purchased 30,602 ordinary shares in the AIM-listed biotechnology firm.
Read moreOpen Orphan agrees acquisition of hVIVO at 34% premium
9th Dec 2019 14:36
(Sharecast News) - Open Orphan, the rare and orphan drug services company, has agreed the takeover of hVIVO by means of an all-share reverse take-over at a 33.8% premium.
Read morePositive results from FLU-v study welcomed by hVIVO
10th Jan 2019 11:54
(Sharecast News) - Clinical development services company hVIVO announced positive results for the primary endpoint, following completion of analysis of samples by NIAID, and additional results from the Phase IIb viral challenge study of FLU-v.
Read more